Takeda officer reports 144,608 ADS stake

Takeda Pharmaceutical filed an initial ownership report for Global Business Development Officer Marcello Pignagnoli Agosti.

Accepted by SEC EDGAR 03/18/2026 - 06:17 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Takeda Pharmaceutical filed an initial ownership report for Global Business Development Officer Marcello Pignagnoli Agosti. He reports direct ownership of 144,608 American Depositary Shares. This total includes 53,850 restricted stock units, each representing one ADS, vesting on July 1, 2026, July 1, 2027, and July 1, 2028 in scheduled installments.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Pignagnoli Agosti Marcello

Role Global Bus. Devel. Officer

Type	Security	Shares	Price	Value
Holding	American Depositary Shares	--	--	--

Holdings: American Depositary Shares — 144,608 shares (Direct)

Footnotes (1)

1. F1. Includes 53,850 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (24,510 shares), July 1, 2027 (19,798 shares) and July 1, 2028 (9,542 shares).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for Takeda (TAK) disclose about Marcello Pignagnoli Agosti?

The Form 3 shows Marcello Pignagnoli Agosti, Takeda’s Global Business Development Officer, directly holding 144,608 American Depositary Shares. It establishes his initial reported ownership position, including both regular shares and restricted stock units granted as part of his compensation.

How many Takeda (TAK) American Depositary Shares does Marcello Pignagnoli Agosti report owning?

He reports direct ownership of 144,608 American Depositary Shares. This figure reflects his total beneficial stake at the time of the filing, combining fully owned shares and unvested restricted stock units that convert into ADSs as they vest over time.

How many restricted stock units are included in Marcello Pignagnoli Agosti’s Takeda (TAK) holdings?

His reported holdings include 53,850 restricted stock units. Each RSU represents a contingent right to receive one American Depositary Share, giving him significant equity-based compensation that will convert into shares if vesting conditions are satisfied.

What is the vesting schedule for Marcello Pignagnoli Agosti’s Takeda (TAK) restricted stock units?

The 53,850 restricted stock units vest in three tranches: 24,510 RSUs on July 1, 2026, 19,798 RSUs on July 1, 2027, and 9,542 RSUs on July 1, 2028. Each vesting date gradually increases his freely owned Takeda ADS holdings.

Does the Takeda (TAK) Form 3 show any recent insider buying or selling activity?

The Form 3 functions as an initial ownership report and does not show explicit buying or selling transactions. It primarily discloses Marcello Pignagnoli Agosti’s existing direct holdings and equity awards rather than documenting a new market trade.

What role does Marcello Pignagnoli Agosti hold at Takeda (TAK) in this ownership report?

He is identified as Takeda’s Global Business Development Officer. This role typically involves overseeing partnerships, licensing, and strategic growth opportunities, and the Form 3 details his equity stake, aligning his incentives with Takeda shareholders through ADS and RSU holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Pignagnoli Agosti Marcello

(Last) (First) (Middle)

300 MASSACHUSETTS AVE.

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Global Bus. Devel. Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
American Depositary Shares	144,608(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 53,850 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (24,510 shares), July 1, 2027 (19,798 shares) and July 1, 2028 (9,542 shares).

Remarks:

Exhibit 24 Power of Attorney

	/s/ Max Heuer, by power of attorney, for Marcello Agosti	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)